These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32422680)

  • 21. The role of the COOH-terminal region of antithrombin III. Evidence that the COOH-terminal region of the inhibitor enhances the reactivity of thrombin and factor Xa with the inhibitor.
    Nishioka J; Suzuki K
    J Biol Chem; 1992 Nov; 267(31):22224-9. PubMed ID: 1331047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and functional characterization of two natural heparin-binding site variants of antithrombin.
    Dinarvand P; Yang L; Villoutreix BO; Rezaie AR
    J Thromb Haemost; 2018 Feb; 16(2):330-341. PubMed ID: 29215785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary Antithrombin Deficiency Presenting with Deep Venous Thrombosis During the Second Pregnancy.
    Yamashita M; Komaki T; Tashiro K; Inada Y; Iwata A; Ogawa M; Morishita E; Miura SI
    Intern Med; 2020 Jan; 59(2):235-239. PubMed ID: 31554754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
    Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
    Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.
    Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K
    Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis.
    Corral J; Huntington JA; González-Conejero R; Mushunje A; Navarro M; Marco P; Vicente V; Carrell RW
    J Thromb Haemost; 2004 Jun; 2(6):931-9. PubMed ID: 15140129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of the mechanism of action of antithrombin and its inherited deficiency states.
    Blajchman MA
    Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S5-11; discussion S59-64. PubMed ID: 8186357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular structural analysis of a novel and de-novo mutation in the SERPINC1 gene associated with type 1 antithrombin deficiency.
    Wang TF; Dawson JE; Forman-Kay JD; Kahr WHA; Williams S; Chan AK; Kumar R
    Br J Haematol; 2017 May; 177(4):654-656. PubMed ID: 27098850
    [No Abstract]   [Full Text] [Related]  

  • 31. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity.
    Devraj-Kizuk R; Chui DH; Prochownik EV; Carter CJ; Ofosu FA; Blajchman MA
    Blood; 1988 Nov; 72(5):1518-23. PubMed ID: 3179438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel mutation of antithrombin deficiency in six family siblings and the clinical combat.
    Nadir Y; Hoffman R; Corral J; Barak Y; Hasin T; Keren-Politansky A; Brenner B
    Thromb Haemost; 2015 Oct; 114(4):859-61. PubMed ID: 26177694
    [No Abstract]   [Full Text] [Related]  

  • 33. c.1058C>T variant in the SERPINC1 gene is pathogenic for antithrombin deficiency.
    Kumar R; Dawson JE; Chan AK; Forman-Kay JD; Kahr WH; Williams S
    Br J Haematol; 2015 Jul; 170(1):123-5. PubMed ID: 25522812
    [No Abstract]   [Full Text] [Related]  

  • 34. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations.
    Aguila S; Navarro-Fernández J; Bohdan N; Gutiérrez-Gallego R; de la Morena-Barrio ME; Vicente V; Corral J; Martínez-Martínez I
    J Thromb Haemost; 2014 Jul; 12(7):1131-40. PubMed ID: 24824609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.
    Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K
    Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.
    Dementiev A; Swanson R; Roth R; Isetti G; Izaguirre G; Olson ST; Gettins PGW
    J Biol Chem; 2013 Nov; 288(47):33611-33619. PubMed ID: 24068708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Met343Val mutation disrupts the shuttling of Trp380 leading to a low-activity conformer of activated protein C and causes thrombosis.
    Zhou S; Li F; Lai Z; Wu X; Yuan J; Wu W; Ding Q; Wang X; Dai J; Xu Q; Lu Y
    J Thromb Haemost; 2024 Aug; 22(8):2270-2280. PubMed ID: 38788977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.
    Rashid Q; Singh P; Abid M; Jairajpuri MA
    J Thromb Thrombolysis; 2012 Aug; 34(2):251-9. PubMed ID: 22453684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.